Home・Elenco Azioni・Gossamer Bio Inc

Gossamer Bio Inc

Chiusa

SettoreSettore sanitario

0.17 13.33

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.15

Massimo

0.19

Metriche Chiave
By Trading Economics
Entrata	64M 17M
Vendite	-7.7M 9.2M
EPS	-0.2
Margine di Profitto	182.94
Dipendenti	161
EBITDA	-28M -71M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	+613.33% upside

Dividendi
By Acuity
Utili prossimi	3 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-18M 68M
Apertura precedente	-13.16
Chiusura precedente	0.17

Notizie sul Sentiment di mercato

By Acuity

50%

150 / 340 Classifica in Healthcare

Gossamer Bio Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 ago 2026, 23:01 UTC

Gossamer Bio Inc. shares are lower in after-market trading amid notable volatility and ongoing geopolitical tensions involving the U.S. and Iran.

22 ago 2026, 00:01 UTC

Gossamer Bio Inc. shares advanced in after-market trading, recovering from earlier lows amid broader market gains despite no specific company news identified.

21 ago 2026, 23:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, following broader market gains despite earlier lower trading. No specific news was identified for the move.

20 ago 2026, 23:01 UTC

Gossamer Bio shares are lower in after-market trading, reflecting broader market pressures following Walmart's disappointing sales growth and guidance.

19 ago 2026, 23:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, following a notable peak earlier in the session. The stock remains below its 20-day moving average.

18 ago 2026, 23:01 UTC

Gossamer Bio Inc shares rose in after-market trading following Tuesday's close, though no specific news was identified to explain the movement.

17 ago 2026, 23:31 UTC

Gossamer Bio Inc shares are sharply higher in after-market trading, rising significantly despite being below its 20-day moving average and recent declines.

15 ago 2026, 00:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, though no specific news explains the movement. The price remains below its 20-day moving average.

14 ago 2026, 22:51 UTC

Gossamer Bio Inc. shares are higher in after-market hours, despite disappointing U.S. retail sales data influencing broader market sentiment.

13 ago 2026, 23:01 UTC

News

Gossamer Bio reported second-quarter net income of $16.9 million and plans to submit a New Drug Application for seralutinib in September 2026. Shares are higher in after-market trading.

12 ago 2026, 23:01 UTC

Gossamer Bio Inc. shares advanced in after-market trading, continuing a strong performance since July 13, despite earlier fluctuations during the session.

11 ago 2026, 23:11 UTC

No specific news was identified for Gossamer Bio Inc. in after-market trading, with shares effectively unchanged since Tuesday's close.

10 ago 2026, 23:01 UTC

Gossamer Bio Inc. shares are higher in after-hours trading, reflecting strong performance and positioning above the 20-day moving average. No specific news was identified.

7 ago 2026, 19:56 UTC

Gossamer Bio Inc shares are higher today amid a weaker jobs report, easing interest rate hike concerns and shifting market sentiment towards a dovish outlook.

6 ago 2026, 23:12 UTC

Gossamer Bio Inc. shares are effectively unchanged in after-market trading, remaining flat within a narrow band. The stock is above its 20-day moving average.

5 ago 2026, 23:36 UTC

Gossamer Bio Inc shares are higher in after-market trading, despite no specific news. The stock is also above its 20-day moving average.

4 ago 2026, 23:01 UTC

Gossamer Bio shares declined after-market, reflecting broader market trends amid falling crude oil prices. Volatility was noted with fluctuations in trading.

3 ago 2026, 23:06 UTC

Gossamer Bio Inc. shares remained roughly flat in after-market hours, with no specific news identified. Broader market sentiment improved following strong manufacturing data.

1 ago 2026, 00:02 UTC

Social Media

Gossamer Bio Inc shares are lower in after-market hours, continuing a downward trend following recent gains tied to an FDA update on Seralutinib.

31 lug 2026, 23:41 UTC

Social Media

Gossamer Bio Inc. shares are higher in after-market trading following an FDA update on Seralutinib, its candidate for pulmonary arterial hypertension.

30 lug 2026, 23:02 UTC

Gossamer Bio Inc is higher in after-market hours, reflecting broader market gains. The stock benefits from positive sentiment in the biotech sector.

29 lug 2026, 22:31 UTC

Gossamer Bio Inc. shares declined in after-market hours, reflecting unusual movement despite being above its 20-day moving average and near a one-month range high.

28 lug 2026, 23:41 UTC

Gossamer Bio Inc. shares are lower in after-market hours amid broader market declines, particularly in Asia's technology sector due to AI spending concerns.

27 lug 2026, 23:51 UTC

Social Media

Gossamer Bio Inc shares are higher in after-market trading following an upgrade to Outperform from Leerink and an FDA regulatory update on Seralutinib.

24 lug 2026, 22:01 UTC

Gossamer Bio Inc shares rose during after-market trading, reflecting notable strength despite mixed global equity market performance and without any specific company news identified.

23 lug 2026, 23:01 UTC

Gossamer Bio Inc's shares are higher in after-market trading, recovering from earlier losses despite no specific news to explain the movement.

22 lug 2026, 23:01 UTC

Gossamer Bio Inc shares are higher in after-market trading, reflecting a notable rise since Wednesday's close amid rising crude oil prices and geopolitical tensions.

21 lug 2026, 21:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, buoyed by positive sentiment from better-than-expected second-quarter results across major companies.

20 lug 2026, 23:01 UTC

Gossamer Bio Inc shares are trading higher in after-market hours, despite no specific news, amid broader market volatility and inflation concerns.

Confronto tra pari

Modifica del prezzo

Gossamer Bio Inc Previsione

Obiettivo di Prezzo

By TipRanks

613.33% in crescita

Previsioni per 12 mesi

Media 1.07 USD 613.33%

Alto 2 USD

Basso 0.28 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Gossamer Bio Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a Gossamer Bio Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

150 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.